QbD Driven Formulation Development, Optimization of Rosuvastatin Calcium Loaded Floating Microballoons: In Vitro and In Vivo Characterization

Q2 Pharmacology, Toxicology and Pharmaceutics
S. Swain, Sasikanth Kothamasu, M. E. Bhanoji Rao, B. R. Jena
{"title":"QbD Driven Formulation Development, Optimization of Rosuvastatin Calcium Loaded Floating Microballoons: In Vitro and In Vivo Characterization","authors":"S. Swain, Sasikanth Kothamasu, M. E. Bhanoji Rao, B. R. Jena","doi":"10.2174/2210303113666230126103055","DOIUrl":null,"url":null,"abstract":"\n\nThe prime intent of this study was to formulate, optimize and evaluate the floating microballoons of rosuvastatin calcium to extend the stomach or gastrointestinal residence time, dissolution rate, and bioavailability of the drug.\n\n\n\nObjective: Rosuvastatin calcium-loaded floating microballoons were prepared by solvent evaporation technique and systematic optimization of such formulations by response surface methodology using Box-Behnken Design, with the selected independent variables like concentration of HPMC K4M (X1), K15M (X2), and K100M (X3) and dependent variables as mean particle size in µm (R1), % entrapment efficiency (R2), and % drug released at 12h (R3).\n\n\n\nFor each of the studied response variables, the trial formulations were subsequently evaluated for in vitro floating lag time, drug content, total floating time, and drug content, and the data analysis through optimization was carried out by placing the experimental data with an appropriate mathematical model.\n\n\n\nIn vivo pharmacokinetics study parameters for the optimized batch showed a 4 to 5 folds elevation of peak plasma concentration (Cmax), the area under the curve (AUC) data, and reduction of time to reach peak concentration (Tmax) value compared to marketed product (p<0.05). As per ICH guidelines, the stability study results show that floating microballoons remain stable for 6 months.\n\n\n\nHence, the floating microballoons of rosuvastatin calcium are a valuable technique to improve the solubility, dissolution, and bioavailability of a poorly water-soluble drug, rosuvastatin calcium.\n","PeriodicalId":11310,"journal":{"name":"Drug Delivery Letters","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210303113666230126103055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

Abstract

The prime intent of this study was to formulate, optimize and evaluate the floating microballoons of rosuvastatin calcium to extend the stomach or gastrointestinal residence time, dissolution rate, and bioavailability of the drug. Objective: Rosuvastatin calcium-loaded floating microballoons were prepared by solvent evaporation technique and systematic optimization of such formulations by response surface methodology using Box-Behnken Design, with the selected independent variables like concentration of HPMC K4M (X1), K15M (X2), and K100M (X3) and dependent variables as mean particle size in µm (R1), % entrapment efficiency (R2), and % drug released at 12h (R3). For each of the studied response variables, the trial formulations were subsequently evaluated for in vitro floating lag time, drug content, total floating time, and drug content, and the data analysis through optimization was carried out by placing the experimental data with an appropriate mathematical model. In vivo pharmacokinetics study parameters for the optimized batch showed a 4 to 5 folds elevation of peak plasma concentration (Cmax), the area under the curve (AUC) data, and reduction of time to reach peak concentration (Tmax) value compared to marketed product (p<0.05). As per ICH guidelines, the stability study results show that floating microballoons remain stable for 6 months. Hence, the floating microballoons of rosuvastatin calcium are a valuable technique to improve the solubility, dissolution, and bioavailability of a poorly water-soluble drug, rosuvastatin calcium.
QbD驱动的瑞舒伐他汀钙负载漂浮微球的配方开发和优化:体外和体内表征
本研究的主要目的是制备、优化和评价瑞舒伐他汀钙漂浮微球,以延长药物在胃或胃肠道的停留时间、溶出率和生物利用度。目的:采用溶剂蒸发法制备瑞舒伐他汀载钙漂浮微球,并采用Box-Behnken设计响应面法对其配方进行系统优化,选取自变量为HPMC K4M (X1)、K15M (X2)、K100M (X3)浓度,因变量为平均粒径µm (R1)、包封效率% (R2)、12h释药% (R3)。针对每个研究的响应变量,对试验配方进行体外漂浮滞后时间、药物含量、总漂浮时间和药物含量的评价,并将实验数据放入合适的数学模型中进行优化数据分析。优化批次的体内药代动力学研究参数显示,与上市产品相比,其血药峰浓度(Cmax)、曲线下面积(AUC)数据提高了4 ~ 5倍,达到血药峰浓度(Tmax)值的时间缩短了(p<0.05)。根据ICH指南,稳定性研究结果表明,漂浮的微型气球在6个月内保持稳定。因此,瑞舒伐他汀钙的漂浮微球是一种有价值的技术,可以改善水溶性差的药物瑞舒伐他汀钙的溶解性、溶解性和生物利用度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Delivery Letters
Drug Delivery Letters Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
1.70
自引率
0.00%
发文量
30
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信